The Protocol Review and Monitoring System (PRMS) of the Indiana University Simon Cancer Center (IUSCC) provides internal oversight of all cancer clinical trials of the IUSCC. The PRMS is the shared responsibility of two committees: 1. The IUSCC Scientific Review Committee (SRC) chaired by Dr. James Croop: The SRC evaluates the scientific merit of all cancer-related clinical trials proposed by Indiana University School of Medicine faculty or faculty of other IU schools who require Cancer Center resources, including patients or tissues, for conduct of a clinical trial. It assures that the disease-oriented groups and the Principal Investigator (PI) have appropriately prioritized the trial relative to the availability of patients and research staff. The SRC is also responsible for the """"""""scoring"""""""" of protocols seeking support from the IUSCC """"""""Protocol Specific Research"""""""" mechanism. 2. The IUSCC Clinical Trials Monitoring Committee (CTMC) chaired by Dr. Romnee Clark: The primary responsibilities of the CTMC are to assess the adequacy of trial-specific data safety monitoring plans (DMSP's) for each protocol reviewed by the SRC, to review IUSCCsponsored studies for patient safety, to ensure protocol and adverse event report compliance, and to conduct internal audits and quality assurance reviews. In this section we will discuss the function of the Scientific Review Committee. The activities of the Clinical Trials Monitoring Committee will be discussed in the Data and Safety Monitoring section. The Clinical Research Committee (CRC) chaired by Dr. Kathy Miller, Interim Associate Director for Clinical Research, oversees the policies and procedures of the SRC and CTMC, receives monthly reports of the activities of these committees, and arbitrates in the event of disputes. An investigator may request informal consultation from the SRC prior to submission of the proposal. Investigators also may seek assistance from a protocol development coordinator for help with protocol development and SRC submission. There are also a variety of protocol templates available on the Cancer Center intranet. After submission, the SRC reviews the protocol document. At the time of the initial review, the CTMC chair evaluates the adequacy of the protocol-specific DSMP, After review, an investigator may meet with a member of the SRC and/or a Cancer Center biostatistician for further guidance. Once a protocol has been approved by the SRC, it is submitted for Institutional Review Board (IRB) review. The IRB receives a copy of the SRC review. No trial can be submitted to the Indiana University-Purdue University at Indianapolis (IUPUI) IRB without prior review by the SRC. The conduct of activated investigator-initiated protocols is monitored by the CTMC (described in the Data and Safety Monitoring section). In the event of significant toxicity and/or protocol regulatory non-compliance, the CTMC chair notifies both the investigator and the CRC of its findings and recommendations. In addition, the CTMC informs the IRB of its findings and recommendations. The CRC reviews and approves the recommendations. In the event of a serious breach of Good Clinical Practice (GCP), the CRC will notify the Director of the IU Simon Cancer Center, who will take appropriate action. It must be emphasized that it is an absolute requirement of the Schools of Medicine and Nursing, as articulated by Deans Craig Brater and Marion Broome, that all cancer clinical or behavioral trials that either are proposed by IU faculty members or proposed by others and that seek the use of IU Simon Cancer Center patients or resources must be submitted for review by the SRC. These protocols must be reviewed and approved by the SRC prior to IRB submission. The IRB will not review cancer trials until they have been approved by the SRC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082709-13
Application #
8321646
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
13
Fiscal Year
2011
Total Cost
$32,512
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Huang, Xinxin; Guo, Bin; Liu, Sheng et al. (2018) Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. Nat Commun 9:2741
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Hoggatt, Jonathan; Singh, Pratibha; Tate, Tiffany A et al. (2018) Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell 172:191-204.e10
Filley, Anna; Henriquez, Mario; Bhowmik, Tanmoy et al. (2018) Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neurooncol 137:469-479
Sishtla, Kamakshi; Pitt, Natalie; Shadmand, Mehdi et al. (2018) Observations on spontaneous tumor formation in mice overexpressing mitotic kinesin Kif14. Sci Rep 8:16152
Koh, Byunghee; Abdul Qayum, Amina; Srivastava, Rajneesh et al. (2018) A conserved enhancer regulates Il9 expression in multiple lineages. Nat Commun 9:4803
Reese, Michael J; Knapp, Deborah W; Anderson, Kimberly M et al. (2018) In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS One 13:e0203517
Singh, Pratibha; Fukuda, Seiji; Liu, Liqiong et al. (2018) Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function. Stem Cells 36:123-129
Olivos 3rd, David J; Perrien, Daniel S; Hooker, Adam et al. (2018) The proto-oncogene function of Mdm2 in bone. J Cell Biochem 119:8830-8840
Shiue, Kevin; Cerra-Franco, Alberto; Shapiro, Ronald et al. (2018) Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol 13:1549-1559

Showing the most recent 10 out of 256 publications